TD Cowen Lifts REGN Target to $980 as Options Turn Bullish Before Earnings

Nine days before Q3 results, Regeneron Pharmaceuticals is collecting analyst upgrades, shedding short interest, and showing the most call-heavy options positioning in weeks.

Analysts Keep Raising the Bar

TD Cowen's Tyler Van Buren lifted his price target this morning to $980 from $960, keeping his Buy rating. That follows UBS analyst Trung Huynh's formal upgrade to Buy on October 15, when he took his target from $660 to $978. Piper Sandler also nudged its target up on October 19, to $865 from $854. The consensus mean now stands at $865.48, against a close of $807.48 on October 20. That is 7.2% implied upside to the average, and the more aggressive Buy targets from UBS and Cowen sit nearly 21% above the current price.

Factor scores back the direction of travel. The 12-month forward EPS year-on-year increase ranks at the 97th percentile. The analyst recommendation differential sits at the 97th percentile as well. EPS momentum ranks at the 83rd percentile over 30 days and the 88th percentile over 90 days.

Options Lean Bullish

The put-call ratio hit 0.80 on October 20, down 2.2 standard deviations from its 20-day mean of 0.83. For a stock whose PCR rarely moves much, that is a statistically notable shift toward calls. The 52-week range runs from 0.44 to 1.13, so 0.80 sits in the lower third, consistent with positioning that favours upside into the October 30 print.

The last two earnings reports moved the stock 9.7% and 6.2% on the day. That history gives context to why options positioning is attracting attention ahead of this quarter.

Short Sellers Step Back

Short interest has fallen 16.2% over the past month to 2.1% of free float, near multi-month lows. The borrow market is not a constraint: availability is effectively uncapped, with 97.5 million shares available to lend against roughly 2.1 million currently borrowed. Cost to borrow ticked up 95% over the past week to 0.35%, but from a low base. At 0.35%, it remains firmly in easy-borrow territory and does not suggest any crowding pressure.

Shares gained 7.2% over the past week. The median gain among Regeneron's closest peers over the same period was 6.2%, so the stock is modestly outpacing its group without running away from it.

Medicaid Data, a Note

ORTEX Alt Data shows Medicaid dollars reimbursed for Regeneron drugs down 26% on Q1 last year, with the figure falling for three consecutive quarters, the most recent period ending January 2026. That is a negative trend on one revenue line, though it covers a period well before the October 30 print and the company's primary growth drivers are its commercial franchises rather than Medicaid reimbursement alone.

Watch the October 30 open. The previous quarter's 9.7% one-day move shows how much the print itself can reset positioning. The analyst target range and the current options skew both point in the same direction; whether earnings confirm that view is what the market settles next Thursday.

---

• REGN close: $807.48 (Oct 20), up 7.2% on the week
• SI % of free float: 2.1%, down 16.2% over one month
• Cost to borrow: 0.35%, up 95% week-on-week but near historic lows
• PCR: 0.80, minus 2.2 standard deviations from 20-day mean
• Consensus price target: $865.48; TD Cowen $980, UBS $978
• Q3 earnings: October 30, 2026